

**TOXICOLOGICAL PROFILE FOR  
ENDOSULFAN**

**U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES  
Public Health Service  
Agency for Toxic Substances and Disease Registry**

September 2000

## **DISCLAIMER**

The use of company or product name(s) is for identification only and does not imply endorsement by the Agency for Toxic Substances and Disease Registry.

## **UPDATE STATEMENT**

Toxicological profiles are revised and republished as necessary, but no less than once every three years. For information regarding the update status of previously released profiles, contact ATSDR at:

Agency for Toxic Substances and Disease Registry  
Division of Toxicology/Toxicology Information Branch  
1600 Clifton Road NE, E-29  
Atlanta, Georgia 30333



## FOREWORD

This toxicological profile is prepared in accordance with guidelines\* developed by the Agency for Toxic Substances and Disease Registry (ATSDR) and the Environmental Protection Agency (EPA). The original guidelines were published in the *Federal Register* on April 17, 1987. Each profile will be revised and republished as necessary.

The ATSDR toxicological profile succinctly characterizes the toxicologic and adverse health effects information for the hazardous substance described therein. Each peer-reviewed profile identifies and reviews the key literature that describes a hazardous substance's toxicologic properties. Other pertinent literature is also presented, but is described in less detail than the key studies. The profile is not intended to be an exhaustive document; however, more comprehensive sources of specialty information are referenced.

The focus of the profiles is on health and toxicologic information; therefore, each toxicological profile begins with a public health statement that describes, in nontechnical language, a substance's relevant toxicological properties. Following the public health statement is information concerning levels of significant human exposure and, where known, significant health effects. The adequacy of information to determine a substance's health effects is described in a health effects summary. Data needs that are of significance to protection of public health are identified by ATSDR and EPA.

Each profile includes the following:

- (A) The examination, summary, and interpretation of available toxicologic information and epidemiologic evaluations on a hazardous substance to ascertain the levels of significant human exposure for the substance and the associated acute, subacute, and chronic health effects;
- (B) A determination of whether adequate information on the health effects of each substance is available or in the process of development to determine levels of exposure that present a significant risk to human health of acute, subacute, and chronic health effects; and
- (C) Where appropriate, identification of toxicologic testing needed to identify the types or levels of exposure that may present significant risk of adverse health effects in humans.

The principal audiences for the toxicological profiles are health professionals at the Federal, State, and local levels; interested private sector organizations and groups; and members of the public.

This profile reflects ATSDR's assessment of all relevant toxicologic testing and information that has been peer-reviewed. Staff of the Centers for Disease Control and Prevention and other Federal scientists have also reviewed the profile. In addition, this profile has been peer-reviewed by a nongovernmental panel and was made available for public review. Final responsibility for the contents and views expressed in this toxicological profile resides with ATSDR.



Jeffrey P. Koplan, M.D., M.P.H.  
Administrator  
Agency for Toxic Substances and  
Disease Registry

### \*Legislative Background

The toxicological profiles are developed in response to the Superfund Amendments and Reauthorization Act (SARA) of 1986 (Public Law 99-499) which amended the Comprehensive Environmental Response, Compensation, and Liability Act of 1980 (CERCLA or Superfund). This public law directed ATSDR to prepare toxicological profiles for hazardous substances most commonly found at facilities on the CERCLA National Priorities List and that pose the most significant potential threat to human health, as determined by ATSDR and the EPA. The availability of the revised priority list of 275 hazardous substances was announced in the *Federal Register* on November 17, 1997 (62 FR 61332). For prior versions of the list of substances, see *Federal Register* notices dated April 29, 1996 (61 FR 18744); April 17, 1987 (52 FR 12866); October 20, 1988 (53 FR 41280); October 26, 1989 (54 FR 43619); October 17, 1990 (55 FR 42067); October 17, 1991 (56 FR 52166); October 28, 1992 (57 FR 48801); and February 28, 1994 (59 FR 9486). Section 104(i)(3) of CERCLA, as amended, directs the Administrator of ATSDR to prepare a toxicological profile for each substance on the list.

## QUICK REFERENCE FOR HEALTH CARE PROVIDERS

Toxicological Profiles are a unique compilation of toxicological information on a given hazardous substance. Each profile reflects a comprehensive and extensive evaluation, summary, and interpretation of available toxicologic and epidemiologic information on a substance. Health care providers treating patients potentially exposed to hazardous substances will find the following information helpful for fast answers to often-asked questions.

---

### *Primary Chapters/Sections of Interest*

**Chapter 1: Public Health Statement:** The Public Health Statement can be a useful tool for educating patients about possible exposure to a hazardous substance. It explains a substance's relevant toxicologic properties in a nontechnical, question-and-answer format, and it includes a review of the general health effects observed following exposure.

**Chapter 2: Health Effects:** Specific health effects of a given hazardous compound are reported by *route of exposure*, by *type of health effect* (death, systemic, immunologic, reproductive), and by *length of exposure* (acute, intermediate, and chronic). In addition, both human and animal studies are reported in this section.

**NOTE:** Not all health effects reported in this section are necessarily observed in the clinical setting. Please refer to the Public Health Statement to identify general health effects observed following exposure.

**Pediatrics:** Four new sections have been added to each Toxicological Profile to address child health issues:

- Section 1.6**     **How Can (Chemical X) Affect Children?**
- Section 1.7**     **How Can Families Reduce the Risk of Exposure to (Chemical X)?**
- Section 2.7**     **Children's Susceptibility**
- Section 5.6**     **Exposures of Children**

### **Other Sections of Interest:**

- Section 2.8**     **Biomarkers of Exposure and Effect**
  - Section 2.11**   **Methods for Reducing Toxic Effects**
- 

### **ATSDR Information Center**

**Phone:** 1-888-42-ATSDR or (404) 639-6357     **Fax:** (404) 639-6359  
**E-mail:** [atsdric@cdc.gov](mailto:atsdric@cdc.gov)     **Internet:** <http://www.atsdr.cdc.gov>

The following additional material can be ordered through the ATSDR Information Center:

*Case Studies in Environmental Medicine: Taking an Exposure History*—The importance of taking an exposure history and how to conduct one are described, and an example of a thorough exposure history is provided. Other case studies of interest include *Reproductive and Developmental Hazards*; *Skin Lesions and Environmental Exposures*; *Cholinesterase-Inhibiting Pesticide Toxicity*; and numerous chemical-specific case studies.

*Managing Hazardous Materials Incidents* is a three-volume set of recommendations for on-scene (prehospital) and hospital medical management of patients exposed during a hazardous materials incident. Volumes I and II are planning guides to assist first responders and hospital emergency department personnel in planning for incidents that involve hazardous materials. Volume III—*Medical Management Guidelines for Acute Chemical Exposures*—is a guide for health care professionals treating patients exposed to hazardous materials.

*Fact Sheets (ToxFAQs)* provide answers to frequently asked questions about toxic substances.

---

### ***Other Agencies and Organizations***

*The National Center for Environmental Health (NCEH)* focuses on preventing or controlling disease, injury, and disability related to the interactions between people and their environment outside the workplace. *Contact:* NCEH, Mailstop F-29, 4770 Buford Highway, NE, Atlanta, GA 30341-3724 • Phone: 770-488-7000 • FAX: 770-488-7015.

*The National Institute for Occupational Safety and Health (NIOSH)* conducts research on occupational diseases and injuries, responds to requests for assistance by investigating problems of health and safety in the workplace, recommends standards to the Occupational Safety and Health Administration (OSHA) and the Mine Safety and Health Administration (MSHA), and trains professionals in occupational safety and health. *Contact:* NIOSH, 200 Independence Avenue, SW, Washington, DC 20201 • Phone: 800-356-4674 or NIOSH Technical Information Branch, Robert A. Taft Laboratory, Mailstop C-19, 4676 Columbia Parkway, Cincinnati, OH 45226-1998 • Phone: 800-35-NIOSH.

*The National Institute of Environmental Health Sciences (NIEHS)* is the principal federal agency for biomedical research on the effects of chemical, physical, and biologic environmental agents on human health and well-being. *Contact:* NIEHS, PO Box 12233, 104 T.W. Alexander Drive, Research Triangle Park, NC 27709 • Phone: 919-541-3212.

---

### ***Referrals***

*The Association of Occupational and Environmental Clinics (AOEC)* has developed a network of clinics in the United States to provide expertise in occupational and environmental issues. *Contact:* AOEC, 1010 Vermont Avenue, NW, #513, Washington, DC 20005 • Phone: 202-347-4976 • FAX: 202-347-4950 • e-mail: [aoec@dgs.dgsys.com](mailto:aoec@dgs.dgsys.com) • AOEC Clinic Director: <http://occ-env-med.mc.duke.edu/oem/aoec.htm>.

*The American College of Occupational and Environmental Medicine (ACOEM)* is an association of physicians and other health care providers specializing in the field of occupational and environmental medicine. *Contact:* ACOEM, 55 West Seegers Road, Arlington Heights, IL 60005 • Phone: 847-228-6850 • FAX: 847-228-1856.



## CONTRIBUTORS

### CHEMICAL MANAGER(S)/AUTHORS(S):

Lori L. Miller, M.P.H.  
ATSDR, Division of Toxicology, Atlanta, GA

Daniel Gefell, M.S.  
Syracuse Research Corporation, North Syracuse, NY

Armando Avallone, B.S.  
Syracuse Research Corporation, North Syracuse, NY

Fernando Llados, Ph.D.  
Syracuse Research Corporation, North Syracuse, NY

### THE PROFILE HAS UNDERGONE THE FOLLOWING ATSDR INTERNAL REVIEWS:

1. Health Effects Review. The Health Effects Review Committee examines the health effects chapter of each profile for consistency and accuracy in interpreting health effects and classifying end points.
2. Minimal Risk Level Review. The Minimal Risk Level Workgroup considers issues relevant to substance-specific minimal risk levels (MRLs), reviews the health effects database of each profile, and makes recommendations for derivation of MRLs.
3. Data Needs Review. The Research Implementation Branch reviews data needs sections to assure consistency across profiles and adherence to instructions in the Guidance.



## PEER REVIEW

A peer review panel was assembled for endosulfan. The panel consisted of the following members:

1. Dr. Joel Coats, Professor, Iowa State University, Department of Entomology, Ames, Iowa;
2. Dr. Syed GhiasUddin, Consultant, Toxicologist, Indiana Department of Environmental Management, Indianapolis, Indiana; and
3. Dr. Melvin Reuber, Consultant, Columbia, Maryland.

These experts collectively have knowledge of endosulfan's physical and chemical properties, toxicokinetics, key health end points, mechanisms of action, human and animal exposure, and quantification of risk to humans. All reviewers were selected in conformity with the conditions for peer review specified in Section 104(I)(13) of the Comprehensive Environmental Response, Compensation, and Liability Act, as amended.

Scientists from the Agency for Toxic Substances and Disease Registry (ATSDR) have reviewed the peer reviewers' comments and determined which comments will be included in the profile. A listing of the peer reviewers' comments not incorporated in the profile, with a brief explanation of the rationale for their exclusion, exists as part of the administrative record for this compound. A list of databases reviewed and a list of unpublished documents cited are also included in the administrative record.

The citation of the peer review panel should not be understood to imply its approval of the profile's final content. The responsibility for the content of this profile lies with the ATSDR.



## CONTENTS

FOREWORD .....	v
QUICK REFERENCE FOR HEALTH CARE PROVIDERS .....	vii
CONTRIBUTORS .....	ix
PEER REVIEW .....	xi
LIST OF TABLES .....	xix
1. PUBLIC HEALTH STATEMENT .....	1
1.1 WHAT IS ENDOSULFAN? .....	1
1.2 WHAT HAPPENS TO ENDOSULFAN WHEN IT ENTERS THE ENVIRONMENT? .....	2
1.3 HOW MIGHT I BE EXPOSED TO ENDOSULFAN? .....	2
1.4 HOW CAN ENDOSULFAN ENTER AND LEAVE MY BODY? .....	3
1.5 HOW CAN ENDOSULFAN AFFECT MY HEALTH? .....	4
1.6 HOW CAN ENDOSULFAN AFFECT CHILDREN? .....	5
1.7 HOW CAN FAMILIES REDUCE THE RISK OF EXPOSURE TO ENDOSULFAN? .....	6
1.8 IS THERE A MEDICAL TEST TO DETERMINE WHETHER I HAVE BEEN EXPOSED TO ENDOSULFAN? .....	7
1.9 WHAT RECOMMENDATIONS HAS THE FEDERAL GOVERNMENT MADE TO PROTECT HUMAN HEALTH? .....	8
1.10 WHERE CAN I GET MORE INFORMATION? .....	9
2. HEALTH EFFECTS .....	11
2.1 INTRODUCTION .....	11
2.2 DISCUSSION OF HEALTH EFFECTS BY ROUTE OF EXPOSURE .....	11
2.2.1 Inhalation Exposure .....	13
2.2.1.1 Death .....	13
2.2.1.2 Systemic Effects .....	13
2.2.1.3 Immunological and Lymphoreticular Effects .....	20
2.2.1.4 Neurological Effects .....	20
2.2.1.5 Reproductive Effects .....	21
2.2.1.6 Developmental Effects .....	21
2.2.1.7 Genotoxic Effects .....	21
2.2.1.8 Cancer .....	22
2.2.2 Oral Exposure .....	22
2.2.2.1 Death .....	22
2.2.2.2 Systemic Effects .....	26
2.2.2.3 Immunological and Lymphoreticular Effects .....	68
2.2.2.4 Neurological Effects .....	69
2.2.2.5 Reproductive Effects .....	73
2.2.2.6 Developmental Effects .....	75
2.2.2.7 Genotoxic Effects .....	77
2.2.2.8 Cancer .....	78
2.2.3 Dermal Exposure .....	81

2.2.3.1	Death	81
2.2.3.2	Systemic Effects	82
2.2.3.3	Immunological and Lymphoreticular Effects	91
2.2.3.4	Neurological Effects	92
2.2.3.5	Reproductive Effects	93
2.2.3.6	Developmental Effects	94
2.2.3.7	Genotoxic Effects	94
2.2.3.8	Cancer	94
2.3	TOXICOKINETICS	94
2.3.1	Absorption	95
2.3.1.1	Inhalation Exposure	95
2.3.1.2	Oral Exposure	95
2.3.1.3	Dermal Exposure	96
2.3.2	Distribution	97
2.3.2.1	Inhalation Exposure	98
2.3.2.2	Oral Exposure	98
2.3.2.3	Dermal Exposure	101
2.3.2.4	Other Routes of Exposure	102
2.3.3	Metabolism	102
2.3.4	Elimination and Excretion	105
2.3.4.1	Inhalation Exposure	105
2.3.4.2	Oral Exposure	105
2.3.4.3	Dermal Exposure	107
2.3.4.4	Other Routes of Exposure	108
2.3.5	Physiologically based Pharmacokinetic (PBPK)/Pharmacodynamic (PD) Models	108
2.4	MECHANISMS OF ACTION	111
2.4.1	Pharmacokinetic Mechanisms	111
2.4.2	Mechanisms of Toxicity	111
2.4.3	Animal-to-Human Extrapolations	115
2.5	RELEVANCE TO PUBLIC HEALTH	115
2.6	ENDOCRINE DISRUPTION	137
2.7	CHILDREN'S SUSCEPTIBILITY	141
2.8	BIOMARKERS OF EXPOSURE AND EFFECT	145
2.8.1	Biomarkers Used to Identify or Quantify Exposure to Endosulfan	146
2.8.2	Biomarkers Used to Characterize Effects Caused by Endosulfan	148
2.9	INTERACTIONS WITH OTHER CHEMICALS	148
2.10	POPULATIONS THAT ARE UNUSUALLY SUSCEPTIBLE	150
2.11	METHODS FOR REDUCING TOXIC EFFECTS	152
2.11.1	Reducing Peak Absorption Following Exposure	152
2.11.2	Reducing Body Burden	153
2.11.3	Interfering with the Mechanism of Action for Toxic Effects	153
2.12	ADEQUACY OF THE DATABASE	153
2.12.1	Existing Information on Health Effects of Endosulfan	154
2.12.2	Identification of Data Needs	156
2.12.3	Ongoing Studies	167
3.	CHEMICAL AND PHYSICAL INFORMATION	169
3.1	CHEMICAL IDENTITY	169
3.2	PHYSICAL AND CHEMICAL PROPERTIES	169

4. PRODUCTION, IMPORT/EXPORT, USE, AND DISPOSAL .....	181
4.1 PRODUCTION .....	181
4.2 IMPORT/EXPORT .....	182
4.3 USE .....	183
4.4 DISPOSAL .....	183
5. POTENTIAL FOR HUMAN EXPOSURE .....	187
5.1 OVERVIEW .....	187
5.2 RELEASES TO THE ENVIRONMENT .....	187
5.2.1 Air .....	189
5.2.2 Water .....	189
5.2.3 Soil .....	190
5.3 ENVIRONMENTAL FATE .....	190
5.3.1 Transport and Partitioning .....	190
5.3.2 Transformation and Degradation .....	194
5.3.2.1 Air .....	194
5.3.2.2 Water .....	194
5.3.2.3 Sediment and Soil .....	195
5.4 LEVELS MONITORED OR ESTIMATED IN THE ENVIRONMENT .....	196
5.4.1 Air .....	196
5.4.2 Water .....	197
5.4.3 Sediment and Soil .....	199
5.4.4 Other Environmental Media .....	200
5.5 GENERAL POPULATION AND OCCUPATIONAL EXPOSURE .....	201
5.6 EXPOSURES OF CHILDREN .....	203
5.7 POPULATIONS WITH POTENTIALLY HIGH EXPOSURES .....	206
5.8 ADEQUACY OF THE DATABASE .....	206
5.8.1 Identification of Data Needs .....	207
5.8.2 Ongoing Studies .....	211
6. ANALYTICAL METHODS .....	213
6.1 BIOLOGICAL SAMPLES .....	213
6.2 ENVIRONMENTAL SAMPLES .....	214
6.3 ADEQUACY OF THE DATABASE .....	218
6.3.1 Identification of Data Needs .....	223
6.3.2 Ongoing Studies .....	224
7. REGULATIONS AND ADVISORIES .....	225
8. REFERENCES .....	235
9. GLOSSARY .....	279
APPENDICES	
A. ATSDR MINIMAL RISK LEVELS AND WORKSHEETS .....	A-1
B. USER'S GUIDE .....	B-1
C. ACRONYMS, ABBREVIATIONS, AND SYMBOLS .....	C-1





## LIST OF FIGURES

2-1	Levels of Significant Exposure to Endosulfan—Inhalation .....	16
2-2	Levels of Significant Exposure to Endosulfan—Oral .....	49
2-3	Proposed Metabolic Pathway for Endosulfan .....	103
2-4	Conceptual Representation of a Physiologically Based Pharmacokinetic (PBPK) Model for a Hypothetical Chemical Substance .....	110
2-5	Existing Information on Health Effects of Endosulfan .....	155
5-1	Frequency of NPL Sites with Endosulfan Contamination .....	188



## LIST OF TABLES

2-1	Levels of Significant Exposure to Endosulfan—Inhalation	14
2-2	Levels of Significant Exposure to Endosulfan—Oral	27
2-3	Levels of Significant Exposure to Endosulfan—Dermal	83
2-4	Genotoxicity of Endosulfan <i>In Vivo</i>	131
2-5	Genotoxicity of Endosulfan <i>In Vitro</i>	132
3-1	Chemical Identity of Endosulfan	170
3-2	Chemical Identity of $\alpha$ -Endosulfan	171
3-3	Chemical Identity of $\beta$ -Endosulfan	172
3-4	Chemical Identity of Endosulfan Sulfate	173
3-5	Physical and Chemical Properties of Endosulfan	174
3-6	Physical and Chemical Properties of $\alpha$ -Endosulfan	176
3-7	Physical and Chemical Properties of $\beta$ -Endosulfan	177
3-8	Physical and Chemical Properties of Endosulfan Sulfate	179
6-1	Analytical Methods for Determining Endosulfan in Biological Samples	215
6-2	Analytical Methods for Determining Endosulfan in Environmental Samples	219
7-1	Regulations and Guidelines Applicable to Endosulfan	226